The market for RET fusion-targeted therapy is poised for significant growth, propelled by increasing recognition of the cancer-causing potential of RET gene fusions and positive results from clinical trials. Approval of targeted drugs like selpercatinib and pralsetinib for RET fusion-positive tumors has further fueled this expansion. The market size is expected to see a notable increase in sales, reaching an estimated value of $X billion in the coming years.